Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137007
Status:
COMPLETED
Last Update Posted:
2011-04-22
First Post:
2005-08-25
Brief Title:
Zithromax EV in Community-Acquired Pneumonia CAP
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Multicenter Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous AmpicillinSulbactam Followed by Oral Azithromycin Plus Intravenous AmpicillinSulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia CAP
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The intravenous IV regimen containing azithromycin Zithromax plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide
This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia In addition this trial will allow investigators to evaluate the safety and toleration of combination therapy
This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia In addition this trial will allow investigators to evaluate the safety and toleration of combination therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None